J. B. Chemicals & Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
J. B. Chemicals & Pharmaceuticals has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 14% per year. J. B. Chemicals & Pharmaceuticals's return on equity is 17.1%, and it has net margins of 17.1%.
Key information
13.89%
Earnings growth rate
13.64%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.49% |
| Revenue growth rate | 14.03% |
| Return on equity | 17.06% |
| Net Margin | 17.10% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
506943: Dividend Decision And Margin Outlook Will Shape A Steady Future
Analysts have inched up their price target for J. B.506943: Board Transitions And Dividend Decision Will Shape A Steady Long Term Outlook
Analysts have nudged their price target on J. B.506943: Torrent Control And New Leadership Will Support A Stronger Long Term Outlook
Analysts have slightly raised their price target for J. B.506943: Torrent Control Shift And Management Changes Will Guide A Steady Outlook
Analysts have nudged their price target for J. B.506943: Torrent Takeover, Leadership Changes And Dividend Will Shape A Steady Outlook
Analysts have nudged their fair value estimate for J. B.506943: Torrent Control, Leadership Changes And Dividend Policy Will Guide A Steady Outlook
Analysts have inched up their price target on J. B.506943: Torrent Control, Leadership Change And Dividend Will Shape A Steady Outlook
Analysts have trimmed their price target for J. B.506943: Torrent Stake Build And Leadership Transition Will Support A More Upbeat View
Analysts have maintained their fair value estimate for J. B.506943: Torrent Acquisition And Merger Terms Will Drive A More Upbeat View
Analysts have nudged their price target on J. B.506943: Fair Stance Will Weigh Torrent Deal And Dubai Subsidiary Expansion
Analysts now place their fair value estimate for J. B.Chronic Therapeutic Demand And CDMO Launches Will Extend Global Reach
With both the future P/E ratio and consensus revenue growth forecasts remaining essentially unchanged, analysts have left the fair value estimate for J. B.
Azmarda's Growth And CDMO Expansion Will Fuel Strong Revenue And Margin Growth
Strong cardiology market growth and strategic product positions signal potential revenue boosts and improved market standing.Revenue & Expenses Breakdown
How J. B. Chemicals & Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 41,478 | 7,095 | 10,427 | 0 |
| 31 Dec 25 | 41,930 | 7,538 | 9,804 | 0 |
| 30 Sep 25 | 40,918 | 7,184 | 9,623 | 0 |
| 30 Jun 25 | 40,075 | 6,851 | 9,446 | 0 |
| 31 Mar 25 | 39,180 | 6,596 | 9,172 | 0 |
| 31 Dec 24 | 38,302 | 6,400 | 8,732 | 0 |
| 30 Sep 24 | 37,113 | 6,111 | 8,516 | 0 |
| 30 Jun 24 | 35,924 | 5,871 | 8,293 | 0 |
| 31 Mar 24 | 34,842 | 5,526 | 8,111 | 0 |
| 31 Dec 23 | 33,848 | 5,141 | 7,687 | 0 |
| 30 Sep 23 | 33,330 | 4,866 | 7,554 | 0 |
| 30 Jun 23 | 32,607 | 4,471 | 7,427 | 0 |
| 31 Mar 23 | 31,493 | 4,098 | 7,278 | 0 |
| 31 Dec 22 | 30,115 | 4,071 | 6,511 | 0 |
| 30 Sep 22 | 28,195 | 3,848 | 6,322 | 0 |
| 30 Jun 22 | 26,031 | 3,715 | 6,020 | 0 |
| 31 Mar 22 | 24,242 | 3,854 | 5,662 | 0 |
| 31 Dec 21 | 23,281 | 4,011 | 4,943 | 0 |
| 30 Sep 21 | 22,757 | 4,713 | 4,596 | 0 |
| 30 Jun 21 | 21,262 | 4,474 | 4,352 | 0 |
| 31 Mar 21 | 20,425 | 4,480 | 4,258 | 0 |
| 31 Dec 20 | 19,576 | 3,975 | 4,247 | 0 |
| 30 Sep 20 | 18,381 | 3,097 | 4,224 | 0 |
| 30 Jun 20 | 18,509 | 3,295 | 4,183 | 0 |
| 31 Mar 20 | 17,747 | 2,720 | 4,068 | 0 |
| 31 Dec 19 | 17,501 | 2,686 | 4,060 | 0 |
| 30 Sep 19 | 17,035 | 2,521 | 3,959 | 0 |
| 30 Jun 19 | 16,824 | 2,098 | 3,926 | 0 |
| 31 Mar 19 | 16,432 | 1,935 | 3,820 | 0 |
| 31 Mar 18 | 14,084 | 1,383 | 3,212 | 0 |
| 31 Mar 17 | 13,443 | 1,841 | 2,798 | 0 |
| 31 Mar 16 | 12,104 | 1,625 | 2,282 | 0 |
Quality Earnings: 506943 has high quality earnings.
Growing Profit Margin: 506943's current net profit margins (17.1%) are higher than last year (16.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506943's earnings have grown by 13.9% per year over the past 5 years.
Accelerating Growth: 506943's earnings growth over the past year (7.6%) is below its 5-year average (13.9% per year).
Earnings vs Industry: 506943 earnings growth over the past year (7.6%) did not outperform the Pharmaceuticals industry 17.2%.
Return on Equity
High ROE: 506943's Return on Equity (17.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/19 17:56 |
| End of Day Share Price | 2026/07/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
J. B. Chemicals & Pharmaceuticals Limited is covered by 23 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| null null | Asian Markets Securities Private Limited |
| Tausif Shaikh | BNP Paribas |